|
|||||
|
|
||||||
Originally published as JCO Early Release 10.1200/JCO.2007.15.3106 on May 27 2008 © 2008 American Society of Clinical Oncology. Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation
From the Department of Hematology, Hôpital Saint Antoine; Acute Leukemia Working Party Registry, European Cooperative Group for Blood and Marrow Transplantation Data and Study Office, Faculté de Médecine St-Antoine Université Pierre et Marie Curie and Institut National de la Santé et de la Recherche Médicale (INSERM) Unit U832; Department of Hematology–Bone Marrow Transplantation (BMT), Hôpital St. Louis, Paris; Centre Hospitalier Universitaire (CHU) Bordeaux Hôpital Haut-Leveque, Pessac; Department of Hematology, Hôpital Purpan CHU, Toulouse; Unité de Transplantation et de Thérapie Cellulaire, Institut Paoli Calmettes, INSERM Unité Medicale de Recherche 599, Marseille; BMT Unit, Hôpital E. Herriot, Lyon; Service dHématologie, Hôpital Jean Minjoz, Besancon; Department of Hematology, Hotel Dieu, Nantes, France; Department of Hematology, Ospedale San Martino, Genova; Dip. Biotecnologie Cellulari ed Ematologia, University La Sapienza, Rome, Italy; and Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands Corresponding author: Norbert C. Gorin, MD, Hopital Saint-Antoine and Université Pierre et Marie Curie UPMC, 184 Rue du Faubourg Saint-Antoine, Cedex 12 Paris, France 75571; e-mail: norbert-claude.gorin{at}sat.aphp.fr Purpose Patients with acute myelocytic leukemia carrying inversion 16 (inv16) or t(8;21) have a better initial response to high-dose cytarabine than patients without these chromosomal abnormalities. They presently do not undergo transplantation in first remission (CR1), but there is concern about late relapses. Patients and Methods From 1990 to 2004, 325 adult patients received transplantations in CR1 (159 patients with inv16 and 166 patients with t(8;21), including 35 and 60 patients, respectively, with additional chromosomal abnormalities). Genoidentical allografts were performed in 64 patients with inv16 and 81 patients with t(8;21), and autografts were performed in 95 patients with inv16 and 85 patients with t(8;21). Results In patients with inv16, after allogeneic and autologous transplantation, the 5-year leukemia-free survival (LFS) rates were 59% and 66% (P = .5), the relapse incidence (RI) rates were 27% and 32% (P = .45), and the transplantation-related mortality (TRM) rates were 14% and 2% (P = .003), respectively. Female patients had a lower RI and a higher LFS. Additional chromosomal abnormalities, compared with no additional abnormalities, were associated with lower RI rate (12% v 34%, respectively; P = .01) and higher 5-year LFS rate (78% v 59%, respectively; P = .04). In patients with t(8;21), after allogeneic and autologous transplantation, the 5-year LFS rates were 60% and 66% (P = .69), the RI rates were 15% and 28% (P = .03), and the TRM rates were 24% and 6% (P = .003), respectively. Younger age and a lower WBC count at diagnosis were associated with a lower TRM and a better LFS. The TRM was lower and the RI was higher in patients with autologous transplantations versus allogeneic transplantations. Conclusion Both autologous and allogeneic transplantation resulted in similar outcomes. Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article. published online ahead of print at www.jco.org on May 27, 2008.
This article has been cited by other articles:
|
||||||||||||
|
|||||||||||
|
Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
|